NCT00476385View on ClinicalTrials.gov

Practicability and Acceptability of Stylomax® in Children

PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

December 31, 2005

Conditions
Growth Hormone Deficiency
Interventions
DRUG

somatropine

subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg

Trial Locations (1)

Unknown

Sanofi-Aventis, Paris

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00476385 - Practicability and Acceptability of Stylomax® in Children | Biotech Hunter | Biotech Hunter